$0.54
+0.00 (+0.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TRAW is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
35 interventional · 1 with posted results
Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 5.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaNCT07371650Incidence of AE/SAERandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: TRX-100, Standard of Care (SOC) | Influenza | 105 | Dec 2026 | ≤ 134 d | 2026-03-27 |
| Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelNCT07503405Laboratory-Confirmed InfectionRandomized · Triple-masked · Prevention | Phase 2 | Not yet recruiting | Drug: TRX-100, Placebo · Biological: Influenza A/France/759/2021 (H1N1) virus | Influenza | 165 | Nov 2026 | ≤ 103 d | 2026-03-31 |
| Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy VolunteersNCT07526506Incidence, severity, and relationship of treatment-emergent adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: TRX-100, Placebo | Healthy Volunteer | 32 | Sep 2026 | ≤ 42 d | 2026-08-03 |
| Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19NCT07157007Safety based on adverse events incidenceRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Ratutrelvir (83-0060) non-randomised, Paxlovid, Ratutrelvir (83-0060) | COVID - 19 | 90 | Feb 2026 | — | 2026-01-21 |
| Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic MalignanciesNCT05705505Dose limiting toxicities (DLTs) will be tabulated and summarized by cohortOpen-label · Treatment | Phase 1/2 | Unknown status | Drug: Narazaciclib, Letrozole 2.5mg | Endometrioid Endometrial Cancer | 60 | Jan 2026 | — | 2023-12-12 |
| A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy VolunteersNCT06757738To assess the safety and tolerability of a single oral administration of TRX-100Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: TRX-100, Placebo | Healthy Volunteer Study | 66 | 2025-01-16actual | — | 2026-01-21 |
| Study of ON 123300 in Patients With Advanced CancerNCT04739293Incidence of Dose Limiting Toxicities (DLT)Open-label · Treatment | Phase 1 | Unknown status | Drug: ON123300 | Solid Tumors, Adult | 36 | Oct 2024 | — | 2023-12-07 |
| Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy VolunteersNCT06402136Incidence of AEsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: 83-0060, Placebo | Healthy Volunteers Only | 57 | 2024-08-09actual | — | 2026-01-22 |
| Oral Rigosertib in Low Risk MDS Patients Refractory to ESAsNCT01904682Hematologic ImprovementOpen-label · Treatment | Phase 2 | Completed | Drug: Oral rigosertib | Myelodysplastic Syndromes | 45 | Dec 2020actual | — | 2021-06-16 |
| Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineNCT01926587Dose escalation part of study: Number of patients in whom Dose a Limiting Toxicity (DLT) are observedOpen-label · Treatment | Phase 1/2 | Completed | Drug: oral rigosertib, Azacitidine | Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | 45 | 2020-12-08actual | — | 2021-06-16 |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMANCT02562443Overall survival of all randomized patients and overall survival of patients scored as IPSS-R very high risk.Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Top line analysis indicated that the study had failed to achieve its primary endpoint. | Drug: rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC), best supportive care (BSC) | Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB | 372 | 2020-07-26actual | — | 2022-09-26 |
| Three Dosing Schedules of Oral Rigosertib in MDS PatientsNCT02075034Micrograms of rigosertib per milliliter of plasmaRandomized · Open-label · Treatment | Phase 1 | Withdrawn | Drug: rigosertib | Myelodysplastic Syndrome | 0 | Aug 2019 | — | 2020-07-01 |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsNCT01241500Overall survivalRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: ON 01910.Na | Myelodysplastic Syndromes, MDS, RAEB, Chronic Myelomonocytic Leukemia | 299 | 2018-10-03actual | — | 2020-06-30 |
| Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineNCT01928537Relationship of bone marrow blast response and overall survival.Open-label · Treatment | Phase 3 | Completed | Drug: rigosertib sodium | Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia | 67 | 2017-06-29actual | — | 2020-06-30 |
| Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid TumorsNCT01168011Adverse EventsOpen-label · Treatment | Phase 1 | Completed | Drug: rigosertib | Solid Tumor | 68 | Dec 2015actual | — | 2017-06-23 |
| Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid TumorsNCT02168725Number of patients with adverse eventsOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was placed on hold by the FDA due to manufacturing issues and was not restarted. | Drug: briciclib | Neoplasms, Advanced Solid Tumor | 26 | Dec 2015actual | — | 2021-06-22 |
| Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic CancerNCT01360853SurvivalRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: ON 01910.Na, Gemcitabine, Gemcitabine | Metastatic Pancreatic Adenocarcinoma | 160 | Jun 2015actual | — | 2016-08-04 |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic SyndromeNCT01584531Number of units of red blood cell transfusionsOpen-label · Treatment | Phase 2 | Completed | Drug: rigosertib | Myelodysplastic Syndrome, MDS, Trisomy 8 | 82 | May 2015actual | — | 2017-06-26 |
| Oral Rigosertib for Squamous Cell CarcinomaNCT01807546Overall response rateOpen-label · Treatment | Phase 2 | Completed | Drug: rigosertib | Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Penile Squamous Cell Carcinoma | 64 | Mar 2015actual | — | 2017-06-26 |
| Safety Study of ON 013105 in Lymphoma and Acute Lymphoid LeukemiaNCT01049113Safety based on adverse events, hematology and chemical laboratory values, urinalysis, coagulation, ECG, vital signs, physical examination.Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Lack of available clinical drug supply | Drug: ON 013105 | Lymphoma, Acute Lymphocytic Leukemia | 7 | Dec 2014actual | — | 2015-12-08 |
| Metabolism and Excretion of [14C]-Rigosertib After Infusion to VolunteersNCT02030639The mean percent of the radioactivity of the administered doses recovered in the urine, feces, and overall (urine + feces)Open-label · Basic science | Phase 1 | Completed | Drug: rigosertib | Healthy | 6 | Dec 2014actual | — | 2017-06-23 |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)NCT00854646Safety data, including laboratory parameters and adverse events, will be collected for all patients in order to determine the qualitative and quantitative toxicity, and reversibility of toxicity, of ON 01910.Na.Open-label · Treatment | Phase 1 | Completed | Drug: ON 01910.Na | Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes | 22 | Nov 2014actual | — | 2018-01-10 |
| Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic SyndromeNCT01048619Hematologic and non-hematologic toxicities and the maximum tolerated dose (MTD) of orally administered ON 01910.Na given twice a day up to 14 days at doses escalating from 70 mg to 700 mgOpen-label · Treatment | Phase 1 | Completed | Drug: ON 01910.Na | Myelodysplastic Syndrome | 36 | Nov 2014actual | — | 2017-06-23 |
| Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck CancerNCT02107235Number of patients who experience dose limiting toxicitiesOpen-label · Treatment | Phase 1 | Completed | Drug: oral rigosertib, cisplatin · Radiation: Radiotherapy | Head and Neck Neoplasms, Carcinoma, Squamous Cell | 2 | Oct 2014actual | — | 2017-06-23 |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)NCT01167166Dose Limiting Toxicity (DLT)Open-label · Treatment | Phase 1/2 | Completed | Drug: rigosertib | Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease, Chronic Myeloid Leukemia | 30 | Dec 2013actual | — | 2017-06-26 |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High RiskNCT00906334Overall Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: ON 01910.Na, ON 01910.Na | Myelodysplastic Syndrome | 14 | Nov 2013actual | — | 2017-06-26 |
| Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLNCT00854945Response as defined per the 2000 International Working Group (IWG) Criteria in patients with MDS.Open-label · Treatment | Phase 1/2 | Completed | Drug: ON 01910.Na | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 36 | Sep 2013actual | — | 2017-06-26 |
| Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid TumorsNCT01125891Adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: gemcitabine, ON 01910.Na | Malignant Neoplasmas, Solid Tumors | 39 | Sep 2011actual | — | 2017-06-23 |
| Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer PatientsNCT00856791results2013-01-08Progression Free SurvivalOpen-label · Treatment | Phase 2 | Completed | Drug: ON 01910.Na | Ovarian Cancer | 1 | Jul 2011actual | — | 2017-07-21 |
| Safety Study of ON 01910.Na in Combination With Irinotecan or OxaliplatinNCT00861328maximum tolerated doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin | Advanced Solid Tumors | 18 | Jul 2011actual | — | 2017-06-23 |
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With HepatomaNCT00861783maximum tolerated doseNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na | Hepatoma, Advanced Solid Tumor | 16 | Jul 2011actual | — | 2017-06-23 |
| Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid TumorsNCT01165905Adverse Events and Laboratory ParametersOpen-label · Treatment | Phase 1 | Completed | Drug: ON 01910.Na, Gemcitabine | Solid Tumor | 10 | Jul 2011actual | — | 2017-06-23 |
| Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced CancerNCT01538537Number of dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: rigosertib sodium | Advanced Cancer, Solid Tumors, Cancer, Neoplasms | 29 | Oct 2010actual | — | 2017-06-23 |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced CancerNCT01538563Number of dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: rigosertib sodium | Solid Tumors, Advanced Cancer, Cancer, Neoplasms | 42 | Jul 2010actual | — | 2017-06-23 |
| Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)NCT00867061Maximum tolerated dose (in Phase 1)Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Mutual decision by site and sponsor because of difficulty recruiting Patients. | Drug: ON 01910.Na Concentrate | Myelodysplastic Syndrome | 0 | Jun 2010 | — | 2017-06-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19